.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
US Department of Justice
US Army
Medtronic
Chubb
Harvard Business School
Farmers Insurance
Colorcon
Chinese Patent Office
Argus Health

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,955,512

« Back to Dashboard

Which drugs does patent 8,955,512 protect, and when does it expire?


Patent 8,955,512 protects ADASUVE and is included in one NDA.

This patent has one hundred and ninety-six patent family members in nineteen countries.

Summary for Patent: 8,955,512

Title:Method of forming an aerosol for inhalation delivery
Abstract: The present invention relates to the inhalation delivery of aerosols containing small particles. Specifically, it relates to a method of forming an aerosol for use in inhalation therapy. The method involves: (a) heating a substrate coated with a composition comprising a drug to form a vapor, wherein the coated composition is in the form of a film less than 10.mu. thick; and, (b) allowing the vapor to cool, thereby forming an aerosol, which is used in inhalation therapy. In another aspect, a method of forming an aerosol for use in inhalation therapy is provided, wherein the method comprises: (a) heating a substrate coated with a composition comprising a drug to form a vapor in less than 100 milliseconds, wherein the vapor has a mass greater than 0.1 mg; and, (b) allowing the vapor to cool, thereby forming an aerosol, which is used in inhalation therapy.
Inventor(s): Hale; Ron L. (Woodisde, CA), Hodges; Craig C. (Walnut Creek, CA), Lloyd; Peter M. (Walnut Creek, CA), Mufson; Daniel (Napa, CA), Rogers; Daniel D. (Oakland, CA), Song; Soonho (Stanford, CA), Wensley; Martin J. (San Francisco, CA), Myers; Daniel J. (Mountain View, CA), McKinney; Jeffrey A. (Foster City, CA), Quintana; Reynaldo J. (Redwood City, CA), Rabinowitz; Joshua D. (Princeton, NJ)
Assignee: Alexza Pharmaceuticals, Inc. (Mountain View, CA)
Application Number:13/851,577
Patent Claim Types:
see list of patent claims
Composition; Device;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Galen Uk ADASUVEloxapinePOWDER;INHALATION022549-001Dec 21, 2012RXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,955,512

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,805,854 Delivery of sumatriptan, frovatriptan or naratriptan through an inhalation route► Subscribe
6,803,031 Delivery of erectile dysfunction drugs through an inhalation route► Subscribe
7,087,218Delivery of diazepam through an inhalation route► Subscribe
7,458,374Method and apparatus for vaporizing a compound► Subscribe
6,740,307 Delivery of .beta.-blockers through an inhalation route► Subscribe
8,074,644Method of forming an aerosol for inhalation delivery► Subscribe
6,814,955 Delivery of physiologically active compounds through an inhalation route► Subscribe
7,063,831Delivery of erectile dysfunction drugs through an inhalation route► Subscribe
7,018,621Delivery of rizatriptan or zolmitriptan through an inhalation route► Subscribe
7,022,312Delivery of antiemetics through an inhalation route► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,955,512

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China101596175► Subscribe
China101623528► Subscribe
Czech Republic20033223► Subscribe
Czech Republic20033249► Subscribe
Germany60220909► Subscribe
Germany60227659► Subscribe
Germany60227660► Subscribe
Germany60228231► Subscribe
Germany60228232► Subscribe
Germany60228703► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Colorcon
Cerilliant
McKesson
Daiichi Sankyo
Express Scripts
QuintilesIMS
Queensland Health
Chubb
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot